CALADRIUS BIOSCIENCES

Caladrius Biosciences is a clinical-stage biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. The company's current product candidates include three developmental treatments for cardiovascular diseases based on CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. and CLBS14, a Phase 3 clinical program in no option refractory disabling angina and recipient of a RMAT designation in the U.S.A.

#SimilarOrganizations #People #Financial #Event #Website #More

CALADRIUS BIOSCIENCES

Social Links:

Facebook

Twitter

Industry:

Biotechnology Pharmaceutical Therapeutics

Founded:

1980-01-01

Address:

Basking Ridge, New Jersey, United States

Country:

United States

Website Url:

http://www.caladrius.com

Total Employee:

101+

Status:

Active

Contact:

(908)842-0100

Total Funding:

165.59 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress

Similar Organizations

arbutus-biopharma-logo

Arbutus Biopharma

Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.

minerva-neuroscience-logo

Minerva Neuroscience

Minerva Neurosciences is a clinical-stage biopharmaceutical company

Current Advisors List

peter-g-traber_image

Peter G. Traber Member Board of Directors @ Caladrius Biosciences
Board_member
2015-02-01

gregory-b-brown-md_image

Gregory B. Brown, MD Chairman Of The Board @ Caladrius Biosciences
Board_member
2016-10-01

Current Employees Featured

anne-c-whitaker_image

Anne C. Whitaker
Anne C. Whitaker Independent Director @ Caladrius Biosciences
Independent Director
2020-10-01

kristen-k-buck_image

Kristen K. Buck
Kristen K. Buck Chief Medical Officer @ Caladrius Biosciences
Chief Medical Officer
2021-09-01

not_available_image

David J. Mazzo
David J. Mazzo President and Chief Executive Officer @ Caladrius Biosciences
President and Chief Executive Officer

Founder

catherine-vaczy_image

Catherine Vaczy

Stock Details

Company's stock symbol is NASDAQ:CLBS

Acquisitions List

Date	Company	Article	Price
2022-04-27	Cend Therapeutics Inc.	Cend Therapeutics Inc. acquired by Caladrius Biosciences	N/A
2014-04-15	California Stem Cell	California Stem Cell acquired by Caladrius Biosciences	124 M USD
2011-07-14	Amorcyte	Amorcyte acquired by Caladrius Biosciences	N/A
2011-01-20	PCT Cell Therapy Services	PCT Cell Therapy Services acquired by Caladrius Biosciences	N/A
2011-01-19	Progenitor Cell Therapy	Progenitor Cell Therapy acquired by Caladrius Biosciences	N/A

Investors List

new-jersey-economic-development-authority_image

Key Employee Changes

Date	New article
2021-09-01	Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D., as Chief Medical Officer

Official Site Inspections

http://www.caladrius.com Semrush global rank: 4.24 M Semrush visits lastest month: 2.76 K

Host Informations
Whois Informations

Loading ...